Consumer Staples

Dermata Reports U.S. Trademark Registration for TOME® Brand

Dermata Therapeutics has received U.S. federal trademark registration for its TOME® skincare brand as the company develops its commercial skincare business.

Published:
Reading Time
2 min

Dermata Therapeutics, Inc. (Nasdaq:DRMA) said on November 18, 2026, that the United States Patent and Trademark Office had granted federal trademark registration for its TOME® brand. The registration number is 8555002.

#Trademark registration and commercial strategy

The San Diego-based company said the registration adds intellectual property protection for its commercial skincare business. Chairman, President and Chief Executive Officer Gerry Proehl said the company has invested resources in developing the TOME brand and that protecting its identity supports Dermata’s commercial strategy.

Dermata also cautioned that statements concerning the adequacy of trademark protection, product launches, market acceptance and potential clinical benefits are subject to risks and uncertainties. The company said registered trademarks may not provide adequate protection for its intellectual property.

#TOME product range

Dermata introduced its first TOME product, Foundational Treatment, in August 2026. The company describes it as a once-weekly, professional-grade skincare treatment intended for use at home and designed to improve the appearance of skin texture, tone and overall radiance.

The TOME line uses what Dermata describes as a “wild harvested freshwater sponge,” an ingredient the company associates with skincare products rooted in history and science. Dermata says the brand is intended to offer products that are “powerful, not punishing.”

#Planned product development

Dermata plans to launch TOME Clearing Treatment for acne in the first half of 2027. The product remains a planned release, and the company’s forward-looking statements regarding launch timing and commercial performance are subject to risks and uncertainties.

The company said it is working to expand awareness of TOME, encourage consumer adoption and establish the line as a differentiated skincare brand. Dermata also referred to recently announced positive clinical data and photographs from a cosmetic clinical study of Foundational Treatment.

#About Dermata Therapeutics

Dermata Therapeutics develops and commercialises direct-to-consumer and professional skincare solutions. The company says it draws on clinical dermatology experience and its proprietary Bioneedle™ technology to develop products for consumer skincare needs. Dermata is headquartered in San Diego, California.

#Key Takeaways

  • Dermata Therapeutics received U.S. federal trademark registration for TOME®, registration number 8555002.
  • The company launched TOME Foundational Treatment in August 2026.
  • Dermata plans to launch TOME Clearing Treatment for acne in the first half of 2027.
  • The company cautioned that trademark protection, product launches, market acceptance and clinical benefits remain subject to risks and uncertainties.

Original source: Read original article

Frequently Asked Questions